1-4 of 4
Edmund Lee
Close
Sort by
Journal Articles

MLN9708 Elicits Pharmacodynamic Response in the Bone Marrow Compartment and Has Strong Antitumor Activity in a Preclinical Intraosseous Model of Plasma Cell Malignancy.

Edmund Lee, Bret Bannerman, Michael Fitzgerald, Jennifer Terkelsen, Daniel Bradley, Zhi Li, Ping Li, Siegfried Janz, Brian G Van Ness, Mark Manfredi, Erik Kupperman
Journal: Blood
Blood (2009) 114 (22): 1834.
https://doi.org/10.1182/blood.V114.22.1834.1834
Published: 2009
Journal Articles

Evaluating the Antitumor Activity of MLN9708 in a Disseminated Mouse Model of Double Transgenic iMyc Ca /Bcl-X L Plasma Cell Malignancy.

Michael Fitzgerald, Yueying Cao, Bret Bannerman, Zhi Li, Olga Tayber, Ping Li, Jennifer Terkelsen, Daniel Bradley, Jonathan Frazer, Lee Silverman, PhD, Siegfried Janz, Brian G Van Ness, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood
Blood (2009) 114 (22): 3835.
https://doi.org/10.1182/blood.V114.22.3835.3835
Published: 2009
Journal Articles

The Novel Proteasome Inhibitor MLN9708 Demonstrates Efficacy in a Genetically-Engineered Mouse Model of DeNovo Plasma Cell Malignancy.

Siegfried Janz, Brian G Van Ness, Vishala Neppalli, Ray Liu, Michael D Pickard, Jennifer Terkelsen, Daniel Bradley, Ling Hu, Erik Kupperman, Mark Manfredi, Edmund Lee
Journal: Blood
Blood (2009) 114 (22): 3849.
https://doi.org/10.1182/blood.V114.22.3849.3849
Published: 2009
Journal Articles

In-Vitro and in-Vivo Evaluation of the Orally Active Proteasome Inhibitor MLN9708 in Hematological Models of Human Cancer.

Erik Kupperman, Edmund Lee, Yueying Cao, Bret Bannerman, Michael Fitzgerald, Allison J Berger, Jie Yu, Julie Zhang, Paul Hales, Frank Bruzzese, Jane Liu, Jonathan Blank, Khristofer Garcia, Christopher Tsu, Larry Dick, Paul Fleming, Li Yu, Mark G Manfredi, Mark Rolfe, Joseph Bolen
Journal: Blood
Blood (2009) 114 (22): 2709.
https://doi.org/10.1182/blood.V114.22.2709.2709
Published: 2009